Our Cell Therapies
We are committed to developing transformative cell therapies to improve outcomes for patients with solid tumors.
Our Cell Therapies
We are committed to developing transformative cell therapies to improve outcomes for patients with solid tumors.
Cell Therapy
Our body’s immune system can recognize cancer cells as abnormal and kill them. However, this process can fail to get rid of cancer cells entirely. Immunotherapy is a treatment for some types of cancer that helps the body’s immune system find and kill cancer cells.
Autologous T-cell therapy is a highly personalized immunotherapy that involves taking cells from the patient, improving their functionality and transferring them back to the patient. By reprogramming the T cells, they can be designed with the potential to address a wide range of diseases, including cancer. Unlike other cancer therapies that might require ongoing treatments, cell therapies often offer a one-time treatment option.
Steps Involved in Treatment with a Cell Therapy
Cell or tissue collection
Manufacturing
(cell reprograming and expansion)
Lymphodepletion
(preparing the body for treatment)
Single dose of cell therapy
Post-treatment monitoring
Why does Lyell focus on solid tumors?
90% of cancers are solid tumors. Yet, cell therapies have shown limited success in treating solid tumors. Our goal is to change this. Our T-cell reprogramming technologies are designed to address efficacy barriers to cell therapy in solid tumors.
Learn MoreLearn more about Lyell's approach and capabilities to tackling solid tumors with cell therapy.
At Lyell, we are applying our technologies to reprogram T cells to resist exhaustion and remain potent. Our two distinct approaches include:
Chimeric antigen receptor (CAR) T-Cell therapy
Some cancer cells have biomarkers or antigens (types of proteins) on their cell surface. CAR T cells are modified to recognize and kill the cancer cells that have a specific biomarker.
Tumor-infiltrating lymphocyte (TIL) therapy
Some cancer-fighting immune cells are able to recognize and infiltrate solid tumors to kill cancer cells. TIL therapy involves collecting tumor cells via surgery and growing large numbers of cancer-fighting T cells that are already found in the tumor.
We use two different and complementary types of reprogramming technologies that are designed to make our cell therapy product candidates more potent and longer lasting to fight solid tumors.
Genetic Reprogramming, which includes our c-Jun overexpression and NR4A3 knockout technologies, aims to delay exhaustion and create more potent T cells with enhanced and long-lasting cancer-fighting ability
Epigenetic Reprogramming, which includes our Epi-R™ manufacturing protocol and Stim-R™ technology, aims to enhance qualities of stemness, persistence and function of T cells to drive potent and long-lasting cancer cell killing
Our Product Candidates
Clinical Trials
The participation of patients and their families in clinical trials enables us to evaluate our investigational product candidates for safety and efficacy. We are driven to defeat cancers and are grateful for those who choose to join us on this journey.
Click the disease areas below to learn more about how we are reprogramming T cells for the potential treatment of solid tumors.
Disease facts:
- Can be an aggressive type of breast cancer that can spread early after diagnosis
- Has few targeted therapies
- Accounts for an estimated 10-15% of invasive breast cancers
LYL797
- Investigational CAR T-cell therapy enhanced with our anti-exhaustion technology designed for improved tumor infiltration and tumor cell killing
- Targets ROR1, a protein expressed in various cancers, including TNBC
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL797 in patients with ROR1+ relapsed or refractory TNBC, NSCLC, platinum-resistant ovarian cancer or endometrial cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Disease facts:
- Leading cause of cancer deaths in the US
- Accounts for 84% of new lung cancer diagnoses each year
- Outcomes are improving with targeted- and immune-therapies, however survival rates are still poor
LYL797
- Investigational CAR T-cell therapy enhanced with our anti-exhaustion technology designed for improved tumor infiltration and tumor cell killing
- Targets ROR1, a protein expressed in various cancers, including NSCLC
LYL845
- Investigational TIL therapy enhanced with our epigenetic reprogramming technology
- Targets multiple antigens
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL797 in patients with ROR1+ relapsed or refractory TNBC, NSCLC, platinum-resistant ovarian cancer or endometrial cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL845 in patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC or colorectal cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Disease facts:
- One of the leading causes of cancer deaths among women
- Only about 20% of ovarian cancers are diagnosed at an early stage
LYL797
- Investigational CAR T-cell therapy enhanced with our anti-exhaustion technology designed for improved tumor infiltration and tumor cell killing
- Targets ROR1, a protein expressed in various cancers, including ovarian cancer
LYL119
- Next-generation investigational CAR T-cell therapy incorporating additional anti-exhaustion technology designed for improved potency
- Targets ROR1, a protein expressed in various cancers, including ovarian cancer
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL797 in patients with ROR1+ relapsed or refractory TNBC, NSCLC, platinum-resistant ovarian cancer or endometrial cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL119 in patients with ROR1+ relapsed or refractory platinum-resistant ovarian cancer or endometrial cancer, with subsequent expansion into other tumor types including NSCLC and TNBC
More info: Email clinicaltrialslyell.com
Disease facts:
- The most prevalent gynecological cancer and the sixth most common malignancy worldwide
- Increasing incidence over the last decade and one of the few cancers with increasing mortality
LYL797
- Investigational CAR T-cell therapy enhanced with our anti-exhaustion technology designed for improved tumor infiltration and tumor cell killing
- Targets ROR1, a protein expressed in various cancers, including endometrial cancer
LYL119
- Next-generation investigational CAR T-cell therapy incorporating additional anti-exhaustion technology designed for improved potency
- Targets ROR1, a protein expressed in various cancers, including endometrial cancer
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL797 in patients with ROR1+ relapsed or refractory TNBC, NSCLC, platinum-resistant ovarian cancer or endometrial cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL119 in patients with ROR1+ relapsed or refractory platinum-resistant ovarian cancer or endometrial cancer, with subsequent expansion into other tumor types including NSCLC and TNBC
More info: Email clinicaltrialslyell.com
Disease facts:
- Accounts for ~1% of all skin cancers
- Responsible for ~80% of skin-cancer-related deaths
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL845 in patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC or colorectal cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com
Disease facts:
- Second most common cause of cancer deaths in the US
- ~25% of patients have metastatic disease at diagnosis
- ~50% of patients will eventually develop metastases
Clinical Trial
Stage: Phase 1 trial to evaluate the safety and tolerability of LYL845 in patients with relapsed and/or refractory metastatic or locally advanced melanoma, NSCLC or colorectal cancer
More info: Visit ClinicalTrials.gov or email clinicaltrialslyell.com